Research
Risk of acute kidney injury associated with the use of fluoroquinolones
Steven T. Bird, Mahyar Etminan, James M. Brophy, Abraham G. Hartzema and Joseph A.C. Delaney
CMAJ July 09, 2013 185 (10) E475-E482; DOI: https://doi.org/10.1503/cmaj.121730
Steven T. Bird
From the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Department of Epidemiology (Bird), Silver Spring, Md; College of Pharmacy and Epidemiology, Pharmaceutical Outcomes and Policy (Bird, Hartzema, Delaney), University of Florida, Gainesville, Fla.; Therapeutic Evaluative Unit of the Provincial Health Services Authority and the Department of Pediatrics (Etminan), Faculty of Medicine, University of British Columbia, Vancouver, BC; McGill University Health Centre (Brophy), Royal Victoria Hospital, Montréal, Que.; and the School of Public Health, Department of Epidemiology (Delaney), University of Washington, Seattle, Wash.
PharmD MSMahyar Etminan
From the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Department of Epidemiology (Bird), Silver Spring, Md; College of Pharmacy and Epidemiology, Pharmaceutical Outcomes and Policy (Bird, Hartzema, Delaney), University of Florida, Gainesville, Fla.; Therapeutic Evaluative Unit of the Provincial Health Services Authority and the Department of Pediatrics (Etminan), Faculty of Medicine, University of British Columbia, Vancouver, BC; McGill University Health Centre (Brophy), Royal Victoria Hospital, Montréal, Que.; and the School of Public Health, Department of Epidemiology (Delaney), University of Washington, Seattle, Wash.
PharmD MScJames M. Brophy
From the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Department of Epidemiology (Bird), Silver Spring, Md; College of Pharmacy and Epidemiology, Pharmaceutical Outcomes and Policy (Bird, Hartzema, Delaney), University of Florida, Gainesville, Fla.; Therapeutic Evaluative Unit of the Provincial Health Services Authority and the Department of Pediatrics (Etminan), Faculty of Medicine, University of British Columbia, Vancouver, BC; McGill University Health Centre (Brophy), Royal Victoria Hospital, Montréal, Que.; and the School of Public Health, Department of Epidemiology (Delaney), University of Washington, Seattle, Wash.
MD PhDAbraham G. Hartzema
From the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Department of Epidemiology (Bird), Silver Spring, Md; College of Pharmacy and Epidemiology, Pharmaceutical Outcomes and Policy (Bird, Hartzema, Delaney), University of Florida, Gainesville, Fla.; Therapeutic Evaluative Unit of the Provincial Health Services Authority and the Department of Pediatrics (Etminan), Faculty of Medicine, University of British Columbia, Vancouver, BC; McGill University Health Centre (Brophy), Royal Victoria Hospital, Montréal, Que.; and the School of Public Health, Department of Epidemiology (Delaney), University of Washington, Seattle, Wash.
PharmD PhDJoseph A.C. Delaney
From the Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Department of Epidemiology (Bird), Silver Spring, Md; College of Pharmacy and Epidemiology, Pharmaceutical Outcomes and Policy (Bird, Hartzema, Delaney), University of Florida, Gainesville, Fla.; Therapeutic Evaluative Unit of the Provincial Health Services Authority and the Department of Pediatrics (Etminan), Faculty of Medicine, University of British Columbia, Vancouver, BC; McGill University Health Centre (Brophy), Royal Victoria Hospital, Montréal, Que.; and the School of Public Health, Department of Epidemiology (Delaney), University of Washington, Seattle, Wash.
PhDData supplements
Related Articles
- (2013). Highlights. CMAJ, 185(10), 855. Accessed April 18, 2024. Retrieved from http://www.cmaj.ca/content/185/10/855.
In this issue
Article tools
Respond to this article
Risk of acute kidney injury associated with the use of fluoroquinolones
Steven T. Bird, Mahyar Etminan, James M. Brophy, Abraham G. Hartzema, Joseph A.C. Delaney
CMAJ Jul 2013, 185 (10) E475-E482; DOI: 10.1503/cmaj.121730
Jump to section
Related Articles
Cited By...
- Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study
- Trimethoprim use for urinary tract infection and risk of adverse outcomes in older patients: cohort study
- Dr Ben Franklin and an unusual modern-day cure for recurrent pleuritis
- Fluoroquinolone-induced serious, persistent, multisymptom adverse effects
- Nonantibiotic Effects of Fluoroquinolones in Mammalian Cells
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology